<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="838">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04609839</url>
  </required_header>
  <id_info>
    <org_study_id>TeleRea'nCo</org_study_id>
    <secondary_id>7883</secondary_id>
    <nct_id>NCT04609839</nct_id>
  </id_info>
  <brief_title>FOLLOW-UP OF PATIENTS WITH COVID-19.</brief_title>
  <acronym>TeleRea'nCo</acronym>
  <official_title>TeleRea'nCo : FOLLOW-UP OF PATIENTS WITH COVID-19.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Some patients admitted to intensive care for a severe form of COVID-19 could have&#xD;
      respiratory, cardiac, renal and neurological sequelae in the medium or long term.&#xD;
&#xD;
      The results of this research will allow an improvement in the understanding and management of&#xD;
      patients in the medium and long term.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 27, 2020</start_date>
  <completion_date type="Anticipated">April 27, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 27, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The presence of respiratory, renal, cardiac, motor, neurological, and psychological sequelae will be assessed by specialist doctors during the 12 months following the patient's discharge from intensive care.</measure>
    <time_frame>The primary endpoint will be measured during 12 months following the patient's discharge from intensive care.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>1) The sequelae by type of impairment will be assessed by specialist doctors at 3, 6 and 12 months</measure>
    <time_frame>At M3 (+/-15 days) : 3 months after patient inclusion-At M6 (+/-15 days) : 6 months after patient inclusion-At M12 (+/-15 days) : 12 months after patient inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2) Number of re-hospitalizations at 3, 6 and 12 months</measure>
    <time_frame>At M3 (+/-15 days) : 3 months after patient inclusion-At M6 (+/-15 days) : 6 months after patient inclusion-At M12 (+/-15 days) : 12 months after patient inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3) Date of death</measure>
    <time_frame>Date of death will be collected from inclusion to M12 (12 months after patient inclusion)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4.1) Quality of life score (SF-36 questionnaire) at 3, 6 and 12 months</measure>
    <time_frame>At M3 (+/-15 days) : 3 months after patient inclusion-At M6 (+/-15 days) : 6 months after patient inclusion-At M12 (+/-15 days) : 12 months after patient inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4.2) The Pittsburgh sleep quality index (PSQI questionnaire) at 3, 6 and 12 months</measure>
    <time_frame>At M3 (+/-15 days) : 3 months after patient inclusion-At M6 (+/-15 days) : 6 months after patient inclusion-At M12 (+/-15 days) : 12 months after patient inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5) Cost of health expenditure</measure>
    <time_frame>The cost of health expenditure will be collected from inclusion to M12 (12 months after patient inclusion)</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Patient Admitted to Intensive Care Unit for COVID-19</condition>
  <arm_group>
    <arm_group_label>Patient admitted to intensive care unit for COVID-19</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Follow-up of patients with COVID-19</intervention_name>
    <description>The presence of sequelae, number of re-hospitalizations, date of death and cost of health expenditure will be collected.&#xD;
The Quality of life score (SF-36 questionnaire) and the Pittsburgh sleep quality index (PSQI questionnaire) will be completed by patients.</description>
    <arm_group_label>Patient admitted to intensive care unit for COVID-19</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient admitted to intensive care unit for COVID-19.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient admitted to intensive care unit for COVID-19&#xD;
&#xD;
          -  Adult patient â‰¥ 18 years old&#xD;
&#xD;
          -  Subject having expressed his non-opposition to the research&#xD;
&#xD;
          -  Subject affiliated to a social health insurance protection scheme or beneficiary of&#xD;
             such a scheme&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject under safeguard of justice&#xD;
&#xD;
          -  Patient under guardianship or curatorship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eric DEMONSANT</last_name>
    <phone>+33 3 88 11 54 15</phone>
    <email>eric.demonsant@chru-strasbourg.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hopitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence KESSLER, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Laurence KESSLER, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 26, 2020</study_first_submitted>
  <study_first_submitted_qc>October 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2020</study_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

